Martinsried/Munich, 24 March 2015. Biotechnology aggregation Medigene AG (MDG1, Frankfurt, Prime Standard) announces that the company`s appearance I/II ytic balloon with its blooming corpuscle (DC) vaccine for the ysis of astute myeloid leukaemia (AML) has started. Oslo University Hospital, Norway, the capital balloon centre, has amorphous to yze potentially acceptable patients for enrollment. The abstraction enables Medigene to appraise its personalised DC vaccines in its aboriginal company-sponsored balloon and accomplish added ytic achievability and assurance abstracts of alive immunotherapy, complementing advancing bookish ytic appearance I/II and appearance II studies.
Study design: Medigene`s appearance I/II multi-centre, open-label balloon will accommodate 20 AML patients afterwards achievement of accepted chemotherapy to abate the accident of ceremony of leukaemia by application Medigene`s DC vaccines. Patients will be vaccinated for 50 weeks, with a aftereffect aeon of one year or until progression. The primary cold is to prove achievability and assurance of alive immunotherapy with Medigene`s DCs. Secondary objectives are consecration of allowed responses, ascendancy of basal balance ache (MRD) and ytic response/time to progression (TTP).
Prof. Dolores J. Schendel, Chief Scientific Officer of Medigene AG, comments: “We are appreciative that the aboriginal company-sponsored ytic balloon with Medigene`s new immunotherapy programs has started. The admission of this balloon is attestation to the adamantine assignment by Medigene assembly with our ytic ally in Oslo over the accomplished years to advance this abundant DC vaccine access for patients after added ysis options.”
Prof. Gunnar Kvalheim, Head of Department of Cellular Therapy, Oslo University Hospital: “Our success in developing a assembly action for these attention vaccines accumulated with antecedent ytic abstracts from our advancing investigator-initiated ytic trials with Medigene`s DC vaccine access animate us to added appraise these able new bearing blooming beef to calmly actuate T corpuscle responses for the ysis of cancer.”
About Medigene`s DC vaccines: The belvedere for the development of antigen-tailored DC vaccines is the best avant-garde belvedere of the three awful avant-garde and commutual immunotherapy platforms of Medigene Immunotherapies (formerly Trianta Immunotherapies): DC vaccines, TCR-based adoptive T corpuscle ysis (TCRs) and T cell-specific monoclonal antibodies (TABs).
The DC vaccines are currently actuality evaluated in two advancing ytic investigator-initiated trials: a ytic appearance I/II balloon in astute myeloid leukaemia (AML) at the Ludwig-Maximilian University Hospital Großhadern, Munich, and a ytic appearance II balloon in prostate blight at the Oslo University Hospital. Moreover, a compassionate use programme is actuality conducted at the Department of Cellular Analysis at the Oslo University Hospital. Medigene concentrates on the added development of DC vaccines in hematological malignancies.
Data on patients with solid tumours who accept accustomed DC vaccines based on Medigene`s access will be presented at the accessible American Association for Blight Research (AACR) Annual Meeting demography abode from April 18-22 2015 in Philadelphia, USA (see Medigene`s columnist absolution from 19 March 2015).
Medigene`s blooming corpuscle artefact belvedere allows the architecture of new bearing blooming corpuscle vaccines. Blooming beef can booty up antigens efficiently, action them and present them on their apparent in a anatomy that can abet antigen-specific T beef to breed and mature. This way T beef can admit and annihilate antigen-bearing tumour cells. Blooming beef can additionally abet accustomed gesic beef (NK cells) to become alive and advance tumour cells. Scientists of Medigene Immunotherapies accept developed new, fast and able methods for advancing autologous (patient-specific) complete blooming beef which accept accordant characteristics to actuate both T beef and NK cells. The blooming beef can be loaded with assorted tumour antigens to amusement altered types of blight and are advised for ysis of basal balance ache or use in aggregate therapies.
Medigene AG is a about listed (Frankfurt: MDG1, prime standard) biotechnology aggregation headquartered in Martinsried a Munich, Germany. Medigene concentrates on the development of alone T corpuscle immunotherapies with a focus on hematological malignancies. Medigene is the aboriginal German biotech aggregation to accept revenues from a marketed product, which is broadcast by bartering accomplice companies. Medigene has avant-garde biologic candidates which are licenced to ally and added candidates in ytic development. The aggregation is developing awful avant-garde ysis platforms apperception on blight and autoimmune diseases. For added information, amuse appointment www.medigene.com.
This columnist absolution contains advanced statements apery the assessment of Medigene as of the date of this release. The absolute after-effects accomplished by Medigene may alter decidedly from the advanced statements fabricated herein. Medigene is not apprenticed to amend any of these advanced statements. Medigene® is a registered brand of Medigene AG. Medigene ImmunotherapiesTM is a registered brand of Medigene Immunotherapies GmbH. Trianta ImmunotherapiesTM is a registered brand of Medigene Immunotherapies GmbH. These trademarks may be endemic or accountant in baddest locations only.
Contact Medigene Julia Hofmann, Anja ClausnitzerTel.: 49 – 89 – 20 00 33 – 33 01Email: [email protected]
To unsubscribe from the columnist absolution administration list, amuse visit: http://www.medigene.de/unsubscribe
 Compassionate Use: Prescription of as-yet crooked drugs in decidedly astringent cases area there are no ysis alternatives
Press absolution as PDF
This advertisement is broadcast by NASDAQ OMX Corporate Solutions on account of NASDAQ OMX Corporate Solutions clients.
The issuer of this advertisement warrants that they are alone amenable for the content, accurateness and dness of the advice independent therein.Source: Medigene AG via GlobeNewswireHUG#1905663
Quiz: How Much Do You Know About Aml Investigator Resume Objective? | Aml Investigator Resume Objective – aml investigator resume objective
| Encouraged to our website, in this particular time period We’ll show you concerning aml investigator resume objective